This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available.
Please stay tuned for additional content of this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Overview
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Global Learning Collaborative (GLC) that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. (GLC) has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.
The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.
Faculty:
Luis Paz-Ares, MD, PhD
Head of Oncology
Hospital Universitario 12 de Octubre
Madrid, Spain
Consulting Fees: AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Gilead Sciences, GlaxoSmithKline (GSK), Janssen Pharmaceuticals, Eli Lilly and Company, Merck & Co. (MSD), Merck KGaA (Darmstadt, Germany), Mirati Therapeutics, Novartis, PharmaMar, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Takeda Pharmaceutical Company
Grants: AstraZeneca, Bristol Myers Squibb, Merck & Co. (MSD), Pfizer
Lauren A. Byers, MD
Professor and Thoracic Section Chief
Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center
Houston, TX
Research: Amgen, AstraZeneca, Jazz Pharmaceuticals
Patent Holder: Molecular subtyping of small cell lung cancer to predict therapeutic responses (U.S. Patent No: 11,732,306); methods and systems for diagnosis, classification, and treatment of small cell lung cancer and other high grade neuroendocrine carcinomas
Consulting Fees: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Daiichi Sankyo, Genentech, Jazz Pharmaceuticals, Novartis, Puma Biotechnology
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Bing-E Xu, PhD, has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP has no relevant relationships to disclose.
- Cindy Davidson has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Identify the biological and clinical rationale underpinning B7-H3 as a therapeutic target for patients with extensive-stage small cell lung cancer (ES-SCLC)
- Select appropriate patient populations for B7-H3–directed antibody-drug conjugate (ADC) therapy in ES-SCLC based on key clinical criteria and trial evidence
- Review recent clinical trial findings on efficacy, intracranial activity, and safety of B7-H3–directed ADCs for ES-SCLC presented at WCLC and ESMO 2025
- Identify the biological and clinical rationale underpinning B7-H3 as a therapeutic target for patients with extensive-stage small cell lung cancer (ES-SCLC)
Target Audience
This activity has been designed to meet the educational needs of oncologists and advance practice practitioners as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with ES-SCLC cancer.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.50 contact hour(s)/0.05 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-25-115-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit(s). Approval is valid until 09/26/2026. PAs should claim only the credit commensurate with the extent of their participation in the activity. Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by independent educational grants from Daiichi Sankyo Inc and Merck Sharpe & Dohme LLC.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
